Abstract
Pneumococcal conjugate vaccines (PCVs) have been on the market since the approval of the seven-valent PCV (PCV7) in 2000. PCV7 was subsequently replaced by higher valency vaccines. Higher valency vaccines provide broader serotype coverage against pneumococcal disease, but breakthrough invasive pneumococcal disease (IPD) has been observed [Balsells 2017, Kandasamy 2020] after PCV7 was replaced by PCV13. Furthermore, in clinical trials serotype-specific IgG geometric mean concentrations (GMCs) decreased from PCV7 to PCV13 for shared serotypes, which may contribute to decreased effectiveness observed after the introduction of PCV13 for shared serotypes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
